Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. - Wikidata - wikimedia - TriplyDB

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.

http://www.wikidata.org/entity/Q45206190

about

Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis Present and future in the treatment of diabetic kidney disease Pericytes, an overlooked player in vascular pathobiology A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression.Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat Blockade of PDGF receptor signaling reduces myofibroblast number and attenuates renal fibrosis.DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes.Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors Rodent models of streptozotocin-induced diabetic nephropathy.Targeting pericyte differentiation as a strategy to modulate kidney fibrosis in diabetic nephropathy.Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis Genetic deletion of cell division autoantigen 1 retards diabetes-associated renal injury Chronic kidney disease growth factors in renal fibrosis.New approaches to the treatment of nephropathy in diabetes.Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.What are new avenues for renal protection, in addition to RAAS inhibition?Emerging drugs for managing kidney disease in patients with diabetes.PDGF and the progression of renal disease.Therapeutic approaches to diabetic nephropathy--beyond the RAS.Signaling pathway factors expression in renal tissue of apoE-knockout mice.Nephronophthisis: should we target cysts or fibrosis?Albumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROS-c-Src kinase-mTOR pathway: effect of imatinib mesylate.Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.Lack of type VIII collagen in mice ameliorates diabetic nephropathy.Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease.CCN3: a novel anti-fibrotic treatment in end-stage renal disease?Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis.PDGF receptor-β uses Akt/mTORC1 signaling node to promote high glucose-induced renal proximal tubular cell collagen I (α2) expression.Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease.Acute Kidney Injury and Progression of Diabetic Kidney Disease.Deletion of platelet-derived growth factor receptor-β improves diabetic nephropathy in Ca²⁺/calmodulin-dependent protein kinase IIα (Thr286Asp) transgenic mice.Osteomeles schwerinae Extract Prevents Diabetes-Induced Renal Injury in Spontaneously Diabetic Torii Rats.

P2860

Q26743407-C8962D21-C250-4FD3-B4B5-652590BFF09A Q26864133-DD8CF84F-2DDA-437B-BD46-02CDD81BB3FD Q28070053-5A994B8C-BF7B-4EF8-974B-CE18301A4ED4 Q28484321-C001F6F6-092F-432A-9ADC-4119DD5070FA Q28568759-4AFFA2E7-C72E-4151-AB8A-782EDBFFF24B Q33930316-CD65121E-BF40-4490-BA6F-CEEF2860D6F4 Q34448719-06281393-5B9C-4697-8875-528FFCF3359A Q35015952-B3BACFF7-A527-4B4F-BDF4-2F66293D0FBA Q35047709-4F5C40CC-6146-400F-B287-D9D1274D9F4A Q35161203-EC2BDC8F-FE85-4D67-BC8E-B1FCA35CDEE3 Q35601594-C72389E5-7BA0-4E35-B959-F7EB29C586EB Q35715738-5C7EA074-DA01-42F5-8EA3-8F71EA59E851 Q35902738-5D4737CA-0591-467E-835F-6E00E816F91E Q36820026-5B7DB6B0-C745-43E6-8B1D-21BB42154D96 Q36908400-C64AD779-B8A5-42A5-B763-350AD278F186 Q37042174-F77D46E3-16B2-4C42-B3FC-FBF00AB993B7 Q37260211-C2C8A242-39BD-4838-BC27-B329C18A865B Q37833133-9D929F2D-C6ED-4C3C-B190-312DC1D74D11 Q37899907-2CC10084-749B-4A38-B633-3FDD0B16FB2E Q37904098-5151F99A-065B-47C0-B5BF-6DCB125C0664 Q37980677-20C6D5FE-89CB-4C89-868C-BAE13C305CBC Q38075029-B1F464D7-19A6-4966-B55B-9F198C3656EE Q38185014-027F4D88-59F6-4E93-B25D-DD28415F2588 Q38209811-76E534E2-75CB-4FC7-8F72-50B91F9A85C6 Q38533698-6A28F667-8B13-4F8E-AD03-880D6EC29352 Q38556258-28D1782E-78F1-4516-8A46-B5A8910A6A76 Q39582921-CA5B55F0-0A0B-4BEB-ABE0-4D12295873ED Q40229471-3D60D832-303E-4DD1-9F4A-690EBDC0015F Q41276445-B7553DC1-F5DB-4C2A-B020-19BD2340E24E Q42015762-0ECD5F54-A07F-447C-AA04-2CE6DF18D0E2 Q42184591-12A109F5-3790-47CA-A1C1-ED04E9BFF061 Q44464485-3F00AE2B-8605-46D9-802E-1D6826B88F79 Q47911791-AE083A37-5ED9-498B-B2F2-68775BF68E0A Q48010780-D870D032-C5AD-4083-8DFB-8293CA6D6425 Q52680904-DD26B4F2-28A0-4CA9-8D8F-83E8F74AF956 Q52724019-91DC720B-B077-492A-B828-565D8CBD097C Q54568475-968C42E2-F52B-49C0-99B7-4D9A177907E1 Q54935923-3B6334D2-5921-4507-AC7C-CFBC02E31926

P2860

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.

http://www.wikidata.org/entity/Q45206190

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.

@en

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.

@nl

type

label

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.

@en

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.

@nl

prefLabel

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.

@en

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.

@nl

P1433

Q45206190-54A96724-FE9A-4DCB-8397-C2368A2BFD09

P1476

Q45206190-DA189D6C-625F-4A3A-93AC-E0A7F90755AF

P2093

Q45206190-24C3A36D-4A01-42EF-9C65-3CD0280A425B

Q45206190-4DC04F78-05FD-40E4-8719-6C6642906604

Q45206190-9561CC2B-3889-4BEA-8273-73A005F412BB

Q45206190-979ACF44-8F08-40D6-8D4B-3C395EA148AF

Q45206190-AA4BE649-B76A-4B73-83CD-A115F8C56BBD

Q45206190-CD8A7F91-AD6B-4EA9-9841-D41EE7C34B38

Q45206190-E7D8FA9F-A617-4BFE-BFD4-7E0A3CB3BA15

P304

Q45206190-C514A4BE-73B2-47B5-950C-577403B02002

P31

Q45206190-0C47E87A-894E-444D-B8C5-271C55FBECCB

P356

Q45206190-89A2E240-B5E5-46CA-9AC7-099968BFE569

P433

Q45206190-9E7FCA9E-321D-444D-9547-573ACD399BD1

P478

Q45206190-6DE294EE-E18D-4FA0-81E3-D4BF881187D3

P577

Q45206190-79C77EB8-15E1-411F-B904-C4F8E29CA0FA

P5875

Q45206190-CEFFC8DA-1F3A-49AE-8F2A-E66A7A4A4B3A

P698

Q45206190-0C9E2301-EDCA-4879-94E0-FEAECBF74F10

P921

Q45206190-7FCDAEDD-D105-415B-83BD-081947D93964

P356

P1433

Journal of the American Society of Nephrology

P1476

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.

@en

P2093

Anna C Calkin

http://www.w3.org/2001/XMLSchema#string

Craig M Smith

http://www.w3.org/2001/XMLSchema#string

Karin Jandeleit-Dahm

http://www.w3.org/2001/XMLSchema#string

Kwee K Seah

http://www.w3.org/2001/XMLSchema#string

Mark E Cooper

http://www.w3.org/2001/XMLSchema#string

Markus Lassila

http://www.w3.org/2001/XMLSchema#string

Terri J Allen

http://www.w3.org/2001/XMLSchema#string

P304

363-373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2004050392

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2004-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8106040

http://www.w3.org/2001/XMLSchema#string

P698

15625075

http://www.w3.org/2001/XMLSchema#string

P921